Clinical study of R-CHOP regimen for relapsed and refractory diffuse large B cell lymphoma

( views:389, downloads:0 )
Author:
SU Jing()
MU Li-jun(Department of Hematology, Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China)
SUN Jian(Department of Hematology, Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China)
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
Volume 21, Issue 10, 2012
DOI:
10.3760/cma.j.issn.1009-9921.2012.10.008
Key Word:
Rituximab;Relapse;Refractory;Diffuse large B cell lymphoma

Abstract: Objective To evaluate the clinical efficacy and toxicity of rituximab combined with CHOP (R-CHOP) in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL).Methods 30 patients were enrolled.All patients,pathologically confirmed to be CD20 positive DLBCL (all in stages Ⅲ-Ⅳ ), were relapsed or refractory after received 2-6 cycles of chemotherapy. Then all of them received R-CHOP schedule for 4 to 6 cycles, each cycle was 21 days. Clinical data before and after R-CHOP were collected.A retrospective analysis of the R-CHOP therapy,either compared to the literature or self-control was performed to evaluate the efficacy and toxicity. Results All the 30 patients were evaluable, induding 15 cases were complete remission (CR), 10 cases were partial remission (PR), 3 cases were stable disease (SD),and 2 cases were progressed disease (PD).The CR rate was 50.0 % (15/30),the total response rate (RR) was 83.3 % (25/30).All patients were well tolerated to the therapy.Only 3 cases were Ⅱ degree neutropenia,1 case was Ⅰ degree thrombocytopenia, and 2 cases suffered nausea and other mild gastrointestinal discomfort. Conclusions R-CHOP regimen could also achieve good response for relapsed or refractory DLBCL significantly.The common adverse effects of rituximab were mild.All the patients were well tolerated.

  • [1]何永明.吉西他滨联合方案治疗复发或难治性非霍奇金淋巴瘤5例.白血病·淋巴瘤,2006,15:49-50
  • [2]Cheson BD,Pfistner B,Juweid ME,et al.Revised response criteria for malignant lymphoma.J Clin Oncol,2007,25:579-586.
  • [3]Lazar AD,Shpilberg O,Shaklai M,et al.Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma. lsr Med Assoc J,2009,11:16-22.
  • [4]Lerner RE,Thomas W,Defor TE,et al.The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant,2007 13:486-492
  • [5]张俊萍,毛光华,冯慧晶.利妥昔单抗联合CHOP化疗方案治疗老年非霍奇金淋巴瘤二例并文献复习.白血病·淋巴瘤,2006,15:383-384.
  • [6]Perosa F, Prete M, Racanelli V, et al. CD20-depleting therapy in autoimmune diseases:from basic research to the clinic.J Intern med.2010,267:260-277.
  • [7]Glennie MJ,French RR,Cragg MS,et al.Mechanisms of killing by anti-CD20 monoclonal antibodies.Mol Immunol,2007,44:3823-3837.
  • [8]Nyman H,Jerkeman M,Karjalainen-Lindsberg ML,et al.Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol, 2009, 22:1094-1101.
  • [9]Feugier P,Van Hoof A,Sebban C.Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe 'Etude des Lymphones de l'Adulte.J Clin Oncol,2005,23:4117-4126.
  • [10]Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation on outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.Blood,2003,102:1989-1996.
  • [11]Tarun K, Andrew DZ, Stephen DN,et al. Rituximab and ICE as second-line therapy hefore autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood,2004,103:3684-3688.
  • [12]L ó pez A,Guti é rrez A,Palacios A,et al.GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma:a phase Ⅱ study.Eur J Haematol,2008,80:127-132.
  • [13]吴宏菊,陈德发,罗晓慧,等.美罗华联合DICE方案治疗复发和难治性侵袭性B细胞淋巴瘤.临床肿瘤学杂志,2006,11:210-212.
  • [14]罗蕾,田昌英.美罗华联合化疗治疗B细胞非霍奇金淋巴瘤副作用的观察及护理.四川肿瘤防治,2007,2:140-142.
  • [15]Niitsu N,Hagiwara Y,Tanae K,et al.Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. Clin Oncol, 2010, 28:5097-5100.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn